BMC Cancer

Table 1 KRAS codon 12/13 status by HRM and pyrosequencing in 61 CRC samples

From: A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing

		HRM		Pyrosequencing
				Run 1		Run 2
Sample	cDNA [ng/μl]	Run 1	Run 2	Result	% mut. Alleles	Result	% mut. Alleles	Final result
1	11	failed	WT ^a	WT				WT
2	31	WT ^a		WT				WT
3	10	WT ^a		G12C	13.4			mut
4	93	WT ^a		WT				WT
5	26	WT ^a		WT				WT
6	27	WT ^a		WT				WT
7	10	WT ^a		WT				WT
8	43	mut		G13D	73.9			mut
9	85	failed	WT	WT				WT
10	N/A	mut		G13D	44.3			mut
11	N/A	failed		G12V	2.6			WT ^b
12	N/A	WT		WT				WT
13	N/A	mut		G12V	41.9			mut
14	126	mut		failed		G12D	65.7	mut
15	133	mut		G12D	74.1			mut
16	97	mut		G13D	52.8			mut
17	47	failed	WT	WT				WT
18	14	failed	WT	WT				WT
19	44	WT ^a		WT				WT
20	20	failed	WT ^a	WT				WT
21	N/A	failed		WT				WT
22	138	mut		G12V	12.9			mut
23	325	mut		G12D	56.1			mut
24	140	WT ^a		WT				WT
25	7	mut		G12C	61.2			mut
26	4	WT ^a		WT				WT
27	27	WT ^a		WT				WT
28	13	WT ^a		WT				WT
29	207	mut		G12D	54.5			mut
30	10	failed	WT	G12V	1.5			WT ^b
31	54	WT ^a		WT				WT
32	120	mut		G12V	29.2			mut
33	33	failed	mut	G12C	33.5			mut
34	N/A	mut		G12C	71.4			mut
35	N/A	WT		WT				WT
36	N/A	failed		WT				WT
37	67	WT ^a		WT				WT
38	137	mut		G12C	76.7			mut
39	63	mut		G12A	56			mut
40	13	WT ^a		WT				WT
41	113	WT ^a		WT				WT
42	82	mut		G12C	75.4			mut
43	39	WT		WT				WT
44	7	WT ^a		G12S	2			WT ^b
45	23	WT ^a		WT				WT
46	24	failed^a		G13D	3.5			WT ^b
47	9	WT ^a		WT				WT
48	34	WT ^a		G12S	2			WT ^b
49	25	WT ^a		WT				WT
50	17	WT		WT				WT
51	5	WT ^a		WT				WT
52	29	WT ^a		WT				WT
53	31	mut		G12D	71.3			mut
54	68	WT		WT				WT
55	93	mut		G12D	74.2			mut
56	221	WT		WT				WT
57	83	WT		WT				WT
58	N/A	WT ^a		G12V	1.2			WT ^b
59	35	mut		G12D	83.3			mut
60	N/A	WT		WT				WT
61	37	WT ^a		WT				WT

^aSkewed HRM curve
^bLOD/threshold for potential low level mutation (cf. Therascreen KRAS Pyro Kit handbook version 1, July 2011): G12D 2.2 %/5.2 %, G12V 1.0 %/4.0 %, G12C 2.1 %/5.1 %, G12S 1.9 %/4.9 %, G13D 1.9 %/4.9 %

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com